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1. Introduction
The quality of cardiovascular risk assessment and subsequent
medical treatment for those at elevated risk is dependent on the pre-
cision of resource allocation. Several confounders may lead to un-
necessary treatments, while those at elevated risk may remain un-
treated. Confounders occur both in calibration and discrimination.
While calibration defines the threshold for individuals, which labels
them as low, intermediate, high or very high subjects, discrimination
describes the diagnostic accuracy of a test to detect those with future
disease (Romanens et al., 2010).
Once a test for cardiovascular risk assessment, such as the
Framingham algorithm, has been derived from a population over dec-
ades, accuracy in different populations and continents still has to be
undertaken (external validation). External validation is however diffi-
cult to obtain because contemporary performance can be assessed only
after decades of observation of the outcome variable. Substitutions are
however possible, e.g. with atherosclerosis imaging of carotid or cor-
onary arteries (Romanens et al., 2017) or by measuring cardiovascular
risk at the time of a cardiovascular event (Mortensen and Falk, 2017).
Other important issues are the demographic or ethnic background of
individuals assessed with such risk tools or the type of occupation.
The working group on lipids and atherosclerosis (AGLA) re-
commends the use of cardiac or cardiovascular risk derived from
PROCAM and SCORE respectively in Switzerland (Eckardstein, 2014).
Based on predefined risk thresholds, a primary care subject is cate-
gorized into low, intermediate or high risk. For PROCAM, the categories
are 0–9%, 10–19% and 20% or more; for SCORE, the categories are
0.0–0.9%, 1.0–4.9% and 5% or more (Piepoli et al., 2016). A major
limitation to calculate global cardiovascular risk is present when single
cardiovascular risk factors are high. Therefore, subjects with LDL above
5.0 mmol/l or systolic blood pressure above 160mmHg are by defini-
tion high risk in Switzerland (for SCORE, the high-risk cutoffs are
8.0 mmol/l for total cholesterol and systolic blood pressure of
180mmHg or more).
The SCORE model based the risk algorithm on observations of fatal
cardiovascular events in 12 European cohorts undergoing baseline ex-
amination between 1967 and 1991 (Conroy et al., 2003). In contrast,
PROCAM was derived from working men, later extended to women
using observations for myocardial infarction only (Assmann et al.,
2007). Therefore, the accuracy of these risk assessment tools may be
different in various populations.
For the purpose of this study, we assess the agreement for a statin
indication in German and Swiss subjects using the PROCAM/AGLA and
the SCORE algorithm at various calibration thresholds.
2. Methods
2.1. Subject selection
Subjects were assessed at the practice based level as described
elsewhere (Romanens et al., 2014). In the Swiss Center in Olten, sub-
jects were referred to a cardiological workup by their primary care
physician (59%) or self-referred after public advertisements for a free of
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charge risk cardiovascular estimate payed for by to the vascular risk
foundation (41%). In Koblenz, all subjects were referred within a
working medicine setting (Adams and Bojara, 2015): subjects came
from enterprises of different industries (chemistry, glass, pharmacy,
administration, metal, social institution, paper, printing, ceramics,
computer science) and 44% were employees, 56% were workman (43%
of workman work in 3-shift with night shift). Subjects had to be free of
cardiovascular symptoms, disease or diabetes mellitus. Laboratory va-
lues (cholesterol, LDL, HDL, triglycerides, fasting glucose), blood
pressure and medical history were measured locally and entered into a
spread-sheet (Excel, Microsoft, Richmond, USA). The recruitment
period was between 2002 and 2017 in the Olten area and between 2011
and 2017 in the Koblenz area without a change in the standards of
assessment.
2.2. Computation of cardiovascular risk
Cardiovascular risk was computed using the published risk formulae
in an Excel spread sheet. We used the European Society of Cardiology
risk calculators for low risk populations (SCORE (Descamps et al.,
2012)) and the German PROCAM risk (Assmann et al., 2007). For
Switzerland, PROCAM risk was multiplied by the factor 0.7 (according
to the Swiss AGLA guidelines 2014 (Eckardstein, 2014)) in order to
calculate the AGLA risk score. For Switzerland, it is recommended that
an AGLA risk below 10% should be viewed as a low coronary risk. An
individual data plot of AGLA versus SCORE was created for the Olten
area.
2.3. Computation of statin indications
We computed a statin indication as present as follows:
A) “AGLA/PROCAM risk 10%–19 % and LDL 3.0–4.9 mmol/l” or
“risk≥ 20% and LDL 2.5–4.9 and BP < 160mmHg” or “AGLA/
PROCAM BP≥160mmHg and LDL≥2.5mmol/l” or “AGLA/
PROCAM BP < 160mmHg and LDL≥5.0mmol/l”.
B) “SCORE risk 1.0%–4.9 % and LDL 3.0–4.9mmol/l” or “risk 1.0–4.9
% and LDL 4.0–4.9 mmol/l” or “risk≥ 5.0 % and LDL
2.5–4.9 mmol/l and BP < 180mmHg” or “SCORE BP≥180mmHg
and LDL≥2.5mmol/l” or “SCORE BP < 180mmHg and
LDL≥5.0mmol/l”.
2.4. Ethical aspects
Subjects with self-referral to the Vascular Risk Foundation gave
written consent. The study protocol was approved by the local ethical
committee of Solothurn, Switzerland. Practice based subjects were en-
tered into an anonymized study registry, for which current legislation in
Switzerland and Germany does not require formal ethical committee
consent.
2.5. Statistics
We used MedCalc software (Version 17.6) to calculate ROC analysis
and weighted Kappa statistics (MedCalc Software bvba, 2017). Level of
statistical significance was set at p < 0.05.
3. Results
3.1. Patient characteristics
We assessed 4,588 healthy German and Swiss subjects aged
40–65 years (Adams et al., n.d.). Clinical information for Swiss (CH)
subjects from the Olten area (N=1,858) was collected and compared
to 2,730 German (DE) subjects from the Koblenz area. CH subjects were
older (55 ± 7 versus 50 ± 6 years) with comparable results for the
number of females (46% and 39% respectively) and current smokers in
each group, for systolic blood pressure, lipids, and global risk scores
(Table 1). The time range and the median time of assessment was be-
tween 2002 and 2017 in the Olten area (median year 2009) and was
between 2008 and 2017 in the Koblenz area (median year 2012).
3.2. Distribution of risk categories and potential for statin indication
In the Olten area, AGLA categorizes 89% as low risk (SCORE 38%),
in the Koblenz area PROCAM and SCORE classification was 83% and
56% respectively. Intermediate risk was found in 10% with AGLA and
in 56% with SCORE (Koblenz: 12% und 41% respectively). High risk
was rare with AGLA (2%) and SCORE with 6% (Koblenz: 4% and 3%
respectively, Table 2). Agreement for risk categories using linear
weighted Kappa statistics was poor in the Olten area between AGLA and
SCORE (weighted Kappa 0.152, 95% CI: 0.127 to 0.177), significantly
lower than in the Koblenz area but remained weak (weighted Kappa
0.385, 95% CI: 0.355 to 0.416, Tables 3a and 3b).
A scatter plot of the Olten area subjects (Fig. 1) shows the dis-
tribution of AGLA versus SCORE across all risk categories.
We found a statin indication based on cardiovascular risk results using
AGLA/PROCAM in 5% in the Olten region and in 9% in the Koblenz region.
Another 13% qualified for statins because of extreme blood pressure or LDL
values in the Olten region (14% in the Koblenz region). In contrast, using
the SCORE calculator, a statin indication was present in 40% for LDL cutoff
between 3.0 and 5.0mmol/l (19% for the LDL cutoff between 4.0 and
4.9mmol/l) in Switzerland (30% and 17% in the Koblenz region, respec-
tively, Table 4). In total, 18% qualified for a statin in the Olten region using
AGLA (PROCAM 22%) and for SCOREwe found a total indication for statins
in 51% in the Olten region (LDL cutoff 3.0–4.9mmol/l).
4. Discussion
The Swiss working group on lipids and atherosclerosis (AGLA) re-
commends to use cardiac risk or cardiovascular risk derived from
PROCAM and SCORE respectively in Switzerland (Eckardstein, 2014).
Table 1
Patient characteristics assessed between 2002 and 2017.
Population characteristics Olten area Koblenz area
N= 1858 2730
Female (%) 850 (46%) 1070 (39%)
Age (± SD) 55 ± 7 50 ± 6
Current smoker (N) 428 (23%) 608 (22%)
Family historya (N) 358 (19%) 615 (23%)
Cholesterol (mmol/l) 5.9 ± 1.1 6.0 ± 1.0
Cholesterol ≥8.0mmol/l (N) 76 (4%) 104 (4%)
LDL (mmol/l) 3.7 ± 1.0 3.9 ± 0.9
LDL≥5.0mmol/l (N) 194 (10%) 278 (10%)
Blood pressure (SD) 128 ± 15 125 ± 16
BP≥180mmHg (N) 8 (0%) 25 (1%)
PROCAM risk (SD) 5.5 ± 6.5 4.9 ± 6.3
AGLA risk (SD) 3.8 ± 4.5 –
SCORE risk (SD) 1.8 ± 1.7 1.3 ± 1.5
a For the occurrence of myocardial infarction or stroke in first relatives
aged< 60 years.
Table 2
distribution of risk categories (in percent) assessed between 2002 and 2017.
Olten area Koblenz area
AGLA SCORE PROCAM SCORE
Low (L) 89% 38% 83% 56%
Intermediate (M) 10% 56% 12% 41%
High (H) 2% 6% 4% 3%
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In this study, we assessed the agreement for the risk categories “low”,
“intermediate” and “high” for both risk calculators in two large in-
dependent populations from the Olten area in Switzerland and the
Koblenz area in Germany and discuss important limitations about ca-
libration and discrimination when using contemporary risk assessment
tools at the population and at the individual level.
We extend and confirm a previous study from the Olten area pub-
lished in 2005 with a wKappa value of 0.22 (Romanens et al., 2009) and
another study from the Lausanne area with again a wKappa value of
0.22 (Riesen et al., 2005) regarding the agreement of risk categories.
The reason for differences between the Olten and the Koblenz area
cannot, however, be elucidated from our data. Fig. 1 gives an im-
pression of a plot of SCORE and AGLA in the Olten area at the in-
dividual level, where it becomes apparent, that many subjects with
AGLA risk below 10% are at intermediate or even at high risk with
SCORE. From this it can be recommended to calculate SCORE in those
with AGLA<10%. However, both AGLA and SCORE were not vali-
dated externally for Switzerland in prospective cohorts.
Most primary care physicians use the AGLA calculator and its in-
herent statin recommendations and may therefore miss up to 72% of
the statin indications given by the presence of pronounced risk factors
as outlined in Table 4.
In 2005, where SCORE recommended statins only in high risk patients
(≥5.0%), we found a statin indication in 713 subjects for AGLA in 19%
and for SCORE in 6% (Romanens et al., 2009). Similarly, using a group of
8,829 subjects from the Lausanne Health Promotion Program (Prior et al.,
2005), a potential statin indication was found for AGLA in 23% and for
SCORE in 2% (Riesen et al., 2005). Compared to 2005, statin indications
based on guidelines revealed stable numbers for AGLA/PROCAM (around
20%) and substantially increased for SCORE from about 2%–6% to
30%–40% for the LDL cutoff 3.0mmol/l. If a more restrictive use of the
statin indication is followed using the European Guidelines on cardiovas-
cular disease prevention in clinical practice (Piepoli et al., 2016), where
statins should “at least be considered” only in SCORE risk ≥5.0% and an
LDL≥4.0mmol/l, then 17%–19% would have a statin indication. If sta-
tins should “at least be considered” only in AGLA/PROCAM risk ≥20%
and or LDL≥5.0mmol/l, then a statin indication would be present in
12% in both the Olten area as well as the Koblenz area (Table 4). The poor
agreement regarding risk categories and the only moderate agreement
regarding statin indications are clinically disturbing. While the re-
commendations for treatment cutoffs in arterial hypertension are clear cut
(Mancia et al., 2013), the recommendations about statins are confusing,
especially when reading the European guidelines (Piepoli et al., 2016):
“Thus treatment may occasionally be considered in moderate risk (1–5%)
individuals, provided that patients are well-informed of the limited abso-
lute risk reduction, and high numbers needed to treat. In higher risk
(5–10%), drug therapy is associated with somewhat larger absolute ben-
efits, and should at least be considered.” This wording reflects a substantial
uncertainty regarding the indication for statins in primary care and may
lead to poor agreement regarding statin indications (Romanens et al.,
2017; Mortensen and Falk, 2017).
Both AGLA and SCORE have been assessed with respect to the risk
category in a cross-sectional study of 3,172 adults without previous
CVD hospitalized with acute coronary syndromes (ACS) at 4 university
centers in Switzerland (Selby et al., 2015). In those ACS patients
without diabetes, AGLA categorized them into low risk in 58%, into
medium risk in 18% and into high risk in 24% (SCORE 36%, 38%, 26%
respectively). Therefore, most ACS patients are categorized into the low
or intermediate risk group, especially prominent for the AGLA risk
calculator. Importantly, of the 3,172 ACS patients, only 16% were
treated with statins at the time of the event, while 69% had a statin
indication based on the ESC primary prevention targets and 55% had a
statin indication with the AGLA 2012 recommendation.
Table 3a
Agreement (weighted kappa statistics) between risk categories for the Olten
area utilizing AGLA and SCORE assessed between 2002 and 2017.
SCORE
L M H
AGLA L 551 697 41
M 1 104 35
H 0 11 14
Weighted Kappa 0.152 (95% confidence interval: 0.127 to 0.177).
Table 3b
Agreement (weighted kappa statistics) between risk categories for the Koblenz
area utilizing PROCAM and SCORE assessed between 2002 and 2017.
SCORE
L M H
PROCAM L 1292 643 10
M 12 254 24
H 0 66 36
Weighted Kappa 0.385 (95% confidence interval: 0.355 to 0.416).
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Fig. 1. Individual data plot of AGLA (horizontal axis) and
SCORE (logarithmic scale, vertical axis) for 10-year risk es-
timates in percent assessed between 2002 and 2017. Green
color denotes low SCORE risk (< 1.0%), yellow denotes in-
termediate SCORE risk (1.0–4.9%) and red denotes high
SCORE risk (≥5%). (For interpretation of the references to
color in this figure legend, the reader is referred to the web
version of this article.)
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According to the European Recommendations, the presence of car-
otid plaque is viewed as a very high risk finding (≥10% cardiovascular
mortality risk in 10 years) (Piepoli et al., 2016). We have published the
amount of carotid plaque using a surface tracing technique (total
plaque area, TPA (Spence et al., 2002)) in 2,202 healthy subjects from
the Olten area and in 2,942 healthy subjects from the Koblenz area
(Romanens et al., 2017). The prevalence of advanced atherosclerosis
(TPA≥80mm2) in middle-aged subjects (40–55 years) was 11% in the
Olten area and was 13% in the Koblenz area. The sensitivity of AGLA in
the Olten area at the 10% threshold was 0% for women and 10% for
men (SCORE at the 1% threshold was 28% and 68%, at the SCORE
threshold of 5% was 0% and 3% respectively). The sensitivity of
PROCAM at the 10% threshold was 4% for women and 45% for men
from the Koblenz area (SCORE at the 1% threshold was 15% and 76%,
at the SCORE threshold of 5% was 0% and 4% respectively (Romanens
et al., 2017), Supplementary tables). Further, we found the area under
the curve to detect TPA≥80mm2 to be significantly lower for AGLA
when compared to SCORE in the Olten area (74.3% versus 77.3%,
p=0.003). Based on these observations, the use of SCORE appears to
be a safer strategy in primary prevention than the use of AGLA both
with respect to calibration and discrimination if a SCORE threshold of
1.0%–4.9% is used for intermediate risk. The low sensitivity for clinical
cardiovascular events and extensive atherosclerosis raises questions
regarding the calibration factor of AGLA, which is PROCAM multiplied
by 0.7. In view of the clinically relevant sensitivity problem of AGLA,
the reduction of myocardial infarction risk by 30% for Switzerland
when compared to Germany needs further validation. Calibration fac-
tors have been proposed for several areas, e.g. Strasbourg (women:
0.88, men 0.90), for ex-Yugoslavia (women 1.24, men 1.37) or for
Poland (women 2.22, men 2.21) (Romanens and Ackermann, 2006). It
may therefore be prudent, not to use the current calibration factor of
0.7 in various ethnic groups living in Switzerland. Poorly performing
calibration factors (low sensitivity for atherosclerosis and outcome) will
unnecessarily delay timely preventive interventions, for instance with
statins. This will lead to a substantial increase in long-term morbidity
and all-cause mortality as has recently been shown for the principle of
compression of morbidity in the Chicago area (Allen et al., 2017). An
important difference between AGLA/PROCAM and SCORE is the out-
come variable estimate, which is myocardial infarction for AGLA/
PROCAM (CHD) and which is myocardial infarction, stroke and cor-
onary revascularisation for SCORE (CVD). According to the numbers of
the Cholesterol Treatment Trialist (CTT) metaanalysis, for every myo-
cardial infarction (17.6% observed in 5 years), another 8% develop a
stroke and another 15.8% need a coronary revascularisation procedure
(Mihaylova et al., 2012). Therefore, CHD risk would have to be mul-
tiplied by a factor 2.35 in order to estimate CVD risk from CHD risk. If
we look at treatment costs in 2011 in Switzerland for myocardial in-
farction (4,780 million Swiss francs) and compare it with the treatment
costs for stroke (3,170 million Swiss francs), then the rationale for es-
timates that include stroke risk becomes evident (Wieser et al., 2014).
As a limitation, the long collection time of data in the Olten area
(2002–2017) might have affected our results.
5. Conclusion
Cardiovascular risk assessment, single risk factors and atherosclerosis
imaging have all limitations with respect to sensitivity and specificity for
future cardiovascular events. Nevertheless, efforts are to be made in
order to improve risk prediction. Assessing calibration and discrimina-
tion in subjects with an acute coronary event may help to adjust risk
thresholds. In the future, atherosclerosis imaging (coronary calcifica-
tions, significant amounts of carotid plaque) may help to adjust for poor
discrimination and may help to prefer one algorithm over the other
within the observed population or calibration factors may be adopted
according to the ethnical background, psychological or work load stress.
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